Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2015. The document summarizes an investor presentation held on November 3, 2015, in New York, where GSK profiled its innovative Research and Development (R&D) portfolio. The company highlighted approximately 40 potential new medicines and vaccines across six core therapeutic areas: HIV & Infectious diseases, Oncology, Immuno-Inflammation, Vaccines, Respiratory, and Rare Diseases.
Key Financial Metrics
The filing text does not provide specific historical financial data such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on R&D pipeline progress and forward-looking strategic expectations.
Material Changes and Pipeline Highlights
GSK outlined significant advancements in its clinical pipeline, noting that approximately 80% of the profiled assets have the potential to be "first-in-class." Key developments include:
- Regulatory Filings: GSK has the potential to file up to 20 assets with regulators before 2020, with seven in advanced late-stage development.
- Respiratory: The European Medicines Agency (EMA) issued a positive opinion for Nucala (mepolizumab) for severe eosinophilic asthma; an FDA decision was expected on November 4, 2015.
- Vaccines: Shingrix (zoster) is expected to have global filings in the second half of 2016. A pentavalent meningococcal vaccine (MenABCWY) is in Phase II.
- HIV: Cabotegravir, a long-acting integrase strand inhibitor, is in Phase II with potential Phase III entry in 2016.
- Oncology: Progress reported on epigenetics (BET and LSD1 inhibitors) and immuno-oncology (TCR therapy and OX40 agonist).
- Rare Diseases: GSK filed for European approval of GSK2696273, a gene therapy for ADA-SCID, marking the first autologous stem cell gene therapy product submitted for marketing application review worldwide.
Guidance, Outlook, and Management Commentary
CEO Sir Andrew Witty emphasized that the portfolio supports the Group's outlook for growth from 2016 to 2020 and value creation beyond 2020. Specific financial expectations reiterated from the May 2015 Investor Day include:
- Sales Target: New Pharmaceutical and Vaccine products launched in the last three years, combined with pipeline assets (specifically Nucala and Shingrix), are expected to generate sales of at least £6 billion per annum by 2020 on a Constant Exchange Rate (CER) basis.
- Earnings Growth: Core Earnings Per Share (EPS) is expected to grow at a mid-to-high single-digit Compound Annual Growth Rate (CAGR) on a CER basis over the 2016-2020 period.
- Development Pipeline: In 2016/2017, GSK plans to start Phase II development of approximately 30 new molecular entities (NMEs) and product line extensions (PLEs), and Phase III development of approximately 20 NMEs and PLEs.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ due to factors including regulatory approvals, clinical trial outcomes, pricing pressures, and legal proceedings. The company notes it undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the FDA decision date and outcome for Nucala (mepolizumab), which was pending as of November 4, 2015.
- Monitor the timeline for global regulatory filings of Shingrix (zoster), targeted for the second half of 2016.
- Track the progress of the gene therapy GSK2696273 for ADA-SCID following its European filing.
- Assess the impact of the generic alternative to Advair in the US on future revenue projections.
- Review the results of the LATTE2 trial for cabotegravir (HIV), with data expected in 2016.